Magdalena Bartuś

ORCID: 0000-0002-0832-5008
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Atrial Fibrillation Management and Outcomes
  • Cardiac Arrhythmias and Treatments
  • Blood Pressure and Hypertension Studies
  • Cardiac Imaging and Diagnostics
  • Cardiac Valve Diseases and Treatments
  • Nitric Oxide and Endothelin Effects
  • Cardiovascular Function and Risk Factors
  • Renal and Vascular Pathologies
  • Cardiac pacing and defibrillation studies
  • Migraine and Headache Studies
  • Aortic Disease and Treatment Approaches
  • Eicosanoids and Hypertension Pharmacology
  • Cardiovascular Health and Disease Prevention
  • Lipoproteins and Cardiovascular Health
  • Venous Thromboembolism Diagnosis and Management
  • Cardiac, Anesthesia and Surgical Outcomes
  • Adenosine and Purinergic Signaling
  • ATP Synthase and ATPases Research
  • Cardiac Ischemia and Reperfusion
  • Acute Myocardial Infarction Research
  • Renin-Angiotensin System Studies
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Atherosclerosis and Cardiovascular Diseases
  • Vascular anomalies and interventions
  • Adipose Tissue and Metabolism

Jagiellonian University
2012-2023

John Paul II Hospital
2014-2018

Farmak (Czechia)
2013

1-methylnicotinamide (MNA) has been considered to be an inactive metabolite of nicotinamide. Here we assessed the anti-thrombotic activity MNA in vivo.Antithrombotic action was studied normotensive rats with extracorporeal thrombus formation (thrombolysis), renovascular hypertensive intraarterial (arterial thrombosis) and a venous thrombosis model (venous thrombosis).MNA (3-100 mg kg(-1)) induced dose-dependent sustained thrombolytic response, associated rise 6-keto-PGF(1alpha) blood....

10.1038/sj.bjp.0707383 article EN British Journal of Pharmacology 2007-07-20

Introduction Left atrial appendage closure (LAAC) with LARIAT offers an alternative to oral anticoagulation (OAC) for patients fibrillation. The aim of this study was present long-term clinical outcomes LAAC in these (AF). Material and methods A prospective, single-center performed 139 undergoing Lariat. Thromboembolic events, severe bleeding mortality rate were recorded. reduction risk thromboembolism after calculated. Results mean CHADS2-score 1.8 ± 1.0, CHA2DS2-VASc score 2.9 1.6 HAS-BLED...

10.1371/journal.pone.0208710 article EN cc-by PLoS ONE 2018-12-19

Recent data suggest that epicardial left atrial appendage closure (LAAC) is associated with several short-term neurohormonal effects. However, the long-term effects are currently unknown.To investigate of percutaneous atial (LAA) exclusion using LARIAT on profiles at follow-up.In a prospective single centre study, 60 patients long-standing, persistent fibrillation (AF) were treated. The major hormones adrenergic system, renin-angiotensin-aldosterone system (RAAS), and natriuretic peptides...

10.3390/jcm11061495 article EN Journal of Clinical Medicine 2022-03-09

Attenuated total reflection Fourier transform infrared spectroscopy (ATR-FTIR) with the use of a slide-on germanium accessory followed by chemometric analysis allowed for providing meaningful information about biochemical composition single endothelial cell. In this work, methodology ATR-FTIR measurements dried cells and immersed in water solution is presented. The contact cell Ge crystal was set up manually monitored through integration amide I band. Additionally, imaging transreflection...

10.1039/c2an35331h article EN The Analyst 2012-01-01

Concomitant diabetes mellitus (DM) in atrial fibrillation (AF) may increase the risk of thromboembolism. Left appendage occlusion (LAAO) is an alternative treatment AF patients whom antithrombotic therapy ineffective or contraindicated. The aim this study was to evaluate long-term efficacy LAAO DM with AF.A retrospective conducted 139 who had undergone and were categorized into two groups: 28 111 without DM. Overall, follow-up period 530 patient-years.Mean CHADS2 CHA2 DS2 -VASc scores higher...

10.1111/1753-0407.12824 article EN Journal of Diabetes 2018-07-12

<b><i>Background:</i></b> Patients surviving an initial stroke present a significantly increased risk for further strokes. Left atrial appendage closure (LAAC) became alternative treatment to pharmacological therapy prevention in fibrillation (AF) patients. <b><i>Objective:</i></b> To evaluate the long-term efficacy of LAAC primary and secondary patients with AF. <b><i>Methods:</i></b> This retrospective study enrolled...

10.1159/000500850 article EN Cerebrovascular Diseases 2019-01-01

Abstract Backgrounds Left atrial appendage occlusion (LAAO) offers an alternative to oral anticoagulation (OAC) for patients with fibrillation (AF). The aim of this study was present long‐term clinical outcomes LAAO in a high risk stroke and thromboembolic events (CHA 2 DS ‐VAS‐score ≥ 2) bleeding (HAS‐BLED score 2). Material Methods A prospective, single‐center performed 120 who were screened the LARIAT. Out these 89 underwent LARIAT placement, 57 had (LAA group). Control Group consisted 31...

10.1002/ccd.28187 article EN Catheterization and Cardiovascular Interventions 2019-03-18

Abstract Background Left atrial appendage closure (LAAC) with LARIAT has emerged as one of the alternatives to oral anticoagulation (OAC) in patients nonvalvular fibrillation (AF). Our aim was study long‐term outcomes undergoing procedure. Methods We analyzed screened for device four centers between December 2009 and June 2012. Out these, who didn't undergo LAAC due unfavorable LAA morphology other preprocedural contraindications were included control group. thromboembolism, bleeding events,...

10.1111/jce.14229 article EN Journal of Cardiovascular Electrophysiology 2019-10-09

Abstract Background Left atrial appendage closure (LAAC) became an alternative method for stroke prevention in patients with non‐valvular fibrillation (AF) intolerant to long term oral anticoagulation therapy. This study aimed compare endocardial (Amulet and LAmbere occluders) epicardial (Lariat) LAAC techniques. Methods A retrospective, observational case‐control included 223 consecutive CHA 2 DS ‐VAS score–matched AF who underwent two centers. Results There were 55 matched cases the mean...

10.1111/jce.14802 article EN Journal of Cardiovascular Electrophysiology 2020-11-04

The effect of epicardial left atrial appendage (LAA) occlusion therapy on lipid and glucose metabolism in fibrillation (AF) patients over the long-term follow-up are unclear.In a single-center prospective observational study, 60 with longstanding persistent AF cardiovascular risk factors had undergone an exclusion procedure. Anthropometric parameters glucose, glycated hemoglobin (HbA1c), insulin, leptin, adiponectin, free fatty acids, beta-hydroxybutyrate, total cholesterol levels were...

10.1111/jce.15604 article EN Journal of Cardiovascular Electrophysiology 2022-06-30

In humans, hypercholesterolemia and hypertension are associated with endothelial dysfunction. Here, we assess whether induces dysfunction in rats pre-existing hypertension. Spontaneously hypertensive (SHR) normotensive controls (WKY) were fed a high-cholesterol diet for 12 weeks, function was assessed isolated thoracic aortic rings. SHR WKY rats, the hypercholesterolemic resulted elevation of total cholesterol low-density lipoprotein levels by approximately 2.5- 4.5-fold, respectively....

10.1124/jpet.105.098798 article EN Journal of Pharmacology and Experimental Therapeutics 2006-03-17

Left atrial appendage occlusion affects systemic coagulation parameters, leading to additional patient-related benefits. The aim of this study was investigate the differences in factor changes 6 months after epicardial left patients with different LAA morphometries. This is first analyze these relationships detail. A prospective 22 consecutive performed. Plasminogen, fibrinogen, tPA concentration, PAI-1, TAFI and computed tomography angiograms were Patients divided into subgroups based on...

10.3390/diseases12010008 article EN cc-by Diseases 2023-12-29

Indications for left atrial appendage occlusion (LAAO) are varied and patients require individual management strategies. However, currently no guidelines exist postprocedure oral anticoagulation (OAC) after an LAAO procedure.To evaluate the effect of OAC on thromboembolism, bleeding mortality following procedure with AF.One hundred thirty-nine consecutive nonvalvular fibrillation (NVAF) who underwent LARIAT device were followed at least 40 months. Decisions about its modifications...

10.5114/aic.2020.93916 article EN cc-by-nc-sa Advances in Interventional Cardiology 2020-01-01

Background: Arterial hypertension is the most common cardiovascular system disease, affecting nearly one billion people worldwide. Despite widespread use of antihypertensive medications, in some groups patients an optimal blood pressure (BP) cannot be achieved. Aim: To assess BP reduction with resistant after a catheter-based renal sympathetic denervation procedure and to report vascular kidney safety one-year follow-up. Methods: Twenty eight diagnosed (median age 52.02 years, range 42–72)...

10.5603/kp.a2013.0357 article EN cc-by-nc-nd Kardiologia Polska 2014-01-10

ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Bartus K, Litwinowicz R, Sadowski J, et al. Clinical factors predicting blood pressure reduction after catheter-based renal denervation. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2018;14(3):270-275. doi:10.5114/aic.2018.78330. APA Bartus, K., Litwinowicz, R., Sadowski, J., Zajdel, W., Brzeziński, M., & M. (2018). Interwencyjnej, 14(3), 270-275....

10.5114/aic.2018.78330 article EN cc-by-nc-sa Advances in Interventional Cardiology 2018-01-01

Aortic stenosis (AS) is the most common valve disease in adult population and its prevalence increases with age. Unfortunately, older age comorbidities significantly increase mortality, operative risk worsen prognosis. In recent years, sutureless bioprosthesis [sutureless-aortic replacement (SU-AVR)] has become an alternative to standard AVR or TAVI high-risk patients. Compared AVR, advantages of SU-AVR include shorter implantation, aortic cross clamp (ACC) cardiopulmonary bypass (CPB) times...

10.21037/jtd.2018.10.10 article EN cc-by-nc-nd Journal of Thoracic Disease 2018-11-01
Coming Soon ...